Navigation Links
RPS Announces Jonathan M. Fishbein, MD as Executive Vice President and Chief Medical Officer
Date:11/13/2012

FORT WASHINGTON, Pa., Nov. 13, 2012 /PRNewswire/ -- ReSearch Pharmaceutical Services, Inc. (RPS), a next generation CRO that provides comprehensive global Phase 1-4 clinical development solutions to the biopharmaceutical and medical device industries, today announced that Jonathan M. Fishbein, M.D. has joined the organization as Executive Vice President and Chief Medical Officer. 

In his role, he will have the responsibility of providing leadership and strategic direction to the Medical, Safety, and Medical Writing departments.  Dr. Fishbein has extensive experience in the planning and execution of clinical research in a broad range of therapeutic areas.

Dr. Fishbein joins RPS having recently served as a Vice President in several medical and scientific capacities at ICON Clinical Research.

Dr. Fishbein has over 20 years experience in clinical and basic research, working in the CRO industry, as well as the Government, academic and non-profit sectors.  Before joining ICON, he simultaneously held the positions of Special Assistant to the Deputy Director of the National institute of Allergy and Infectious Diseases (NIAID) and Senior Fellow at the International Center for Research on Women. Prior to those positions, he served as the first Director of the Office for Policy in Clinical Research Operations (OPCRO) at the NIAID's Division of AIDS.  In that role, Dr. Fishbein enforced compliance with regulations, guidance and policies to assure that federally-funded clinical research in HIV/AIDS met established standards of quality, integrity and ethics to protect the safety, rights, and confidentiality of human research subjects.

Before government service, he held various roles at PAREXEL International Corporation, including Vice President of North American Medical Services.

A surgeon by training, Dr. Fishbein was a Medical Staff Fellow at the National Cancer Institute (Immunology Branch) and a Fellow in Transplantation Immunology at the Transplantation Biology Research Center at the Massachusetts General Hospital/Harvard Medical School.  

"Jonathan brings significant expertise to RPS, and we are extremely pleased to welcome him as a member of our Executive Management Team. His addition builds on the depth and breadth of our strategic medical affairs leadership, and allows RPS to continue the growth of our global drug safety organization," said Alan Morgan, Chief Operating Officer.

About RPS

RPS provides comprehensive global Phase I-IV clinical development solutions to the Pharmaceutical, Biotechnology, Medical Device and Diagnostic industries.  By combining our highly experienced clinical research operations infrastructure with the industry's largest resourcing engines, RPS is uniquely positioned to offer our Customers a broad spectrum of outsourcing solutions. These solutions range from globally Embedded functional and cross-functional programs to enhanced global full-service solutions, and are powered by highly experienced project teams providing innovative, seamless, cost-effective and high quality services.

With more than 5,000 employees, RPS operates in more than 64 countries across the globe.


'/>"/>
SOURCE ReSearch Pharmaceutical Services, Inc.
Copyright©2012 PR Newswire.
All rights reserved

Related medicine technology :

1. Edison Pharmaceuticals Announces Initiation of EPI-743 Phase 2B Leigh Syndrome Clinical Trial
2. Developmental Disabilities Software announces Safe Harbor Self-Certification Compliance
3. Hologic Announces Fourth Quarter and Fiscal 2012 Operating Results
4. Regulus Announces Timing for Third Quarter 2012 Financial Results Webcast and Conference Call
5. Valeritas Announces The Publication Of A Retrospective Analysis Of Patient-Reported Data On The V-Go In The Current Issue Of Endocrine Practice
6. Cynosure, Inc. Announces Proposed Public Offering of Class A Common Stock
7. 3SBio Inc. Announces Unaudited Third Quarter 2012 Results
8. Jazz Pharmaceuticals Announces Participation In Three Investor Conferences In November
9. FDAnews announces Fifth Annual Risk Management & Drug Safety Summit
10. Telik Announces Third Quarter 2012 Financial Results
11. Cannabis Science Provides Corporate Guidance on Preclinical Initiatives and Recent Corporate Developments for its Shareholders; CBIS Announces plans for 1st Q of 2013 Webinar Investor Call
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:5/10/2017)... 2017 Global Health Intelligence (GHI), the ... , published its 2017 ranking of the Best-Equipped ... extensive data analysis from GHI,s hospitals database for Latin ... the region. The GHI database covers 86% of the hospitals ... 130 data points for each institution in key areas such ...
(Date:5/9/2017)... 2017  Demonstrating its commitment to representing research- ... the Pharmaceutical Research and Manufacturers of America (PhRMA) ... will now have to meet new research and ... to join PhRMA. "By putting in ... a clear message that being a member of ...
(Date:5/6/2017)... --  Provista , a proven leader in the supply chain ... Jim Cunniff as the company,s new president and ... to Provista, including most recently serving as the president and ... . He assumed his new role with Provista on May ... Provista," says Jody Hatcher , president, Sourcing and Collaboration ...
Breaking Medicine Technology:
(Date:5/24/2017)... ... May 24, 2017 , ... ... (PVDF) based sleep diagnostics sensors, announced today it had completed the first phase ... a mix of domestic and rest of world (ROW) authorized dealers specializing in ...
(Date:5/23/2017)... Pa. (PRWEB) , ... May 23, 2017 , ... ... plans to open The Alexis Joy D’Achille Center for Women’s Behavioral Health at ... care available in western Pennsylvania for women suffering from pregnancy-related depression. Construction of ...
(Date:5/23/2017)... , ... May 23, 2017 , ... New England Journal ... Crisis Worthy of a Policy Response”, -The Rory Staunton Foundation Calls on Health & ... for the Prevention of Sepsis ( http://www.rorystauntonfoundation.org ) today reported on a new study ...
(Date:5/23/2017)... ... May 23, 2017 , ... London, May 23, 2017: Walter Schindler, the Founder ... as a Guest Speaker and Contributor to a weeklong series of classes, meetings, field ... , Walter Schindler and SAIL Capital have received an ...
(Date:5/23/2017)... ... May 23, 2017 , ... Drs. Allen ... peri-implantitis in Las Vegas, NV, and the importance of treating it ... consultation and leading care for peri-implantitis, with or without a referral. As experienced ...
Breaking Medicine News(10 mins):